'Patients' Tag

• Relaxation therapy as effective as massage therapy

  March 10, 2010

  [Story ID: 773]
  A new randomized trial shows that on average, three months after receiving a series of 10 massage sessions, patients had half the symptoms of anxiety.

  posted in Uncategorized by admin

• Shoulder motion after rotator cuff surgery remains different: Study

  March 8, 2010

  [Story ID: 735]
  Shoulder motion after rotator cuff surgery remains significantly different when compared to the patient’s opposite shoulder, according to Henry Ford Hospital researchers.

  posted in Uncategorized by admin

• Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

  March 4, 2010

  [Story ID: 682]
  Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between patients age 70 and over and younger patients with non-small cell lung cancer (NSCLC) receiving salvage targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy.

  posted in Uncategorized by admin

• Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

  February 26, 2010

  [Story ID: 609]
  A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.

  posted in Uncategorized by admin

• Researchers find gene mutations that may provide clues for treating AML patients

  February 19, 2010

  [Story ID: 420]
  Although leukemia is one of the best studied cancers, the cause of some types is still poorly understood. Now, a newly found mutation in acute myeloid leukemia patients could account for half of the remaining cases of adult acute leukemia with an unknown origin.

  posted in Uncategorized by admin

• Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

  February 5, 2010

  [Story ID: 219]
  Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’

  posted in Uncategorized by admin